Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer

Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute, discusses updated findings from the phase 3 S0221 trial (NCT00070564) investigating alternative adjuvant anthracycline and taxane dosing schedules in patients with high-risk, early breast cancer.

Videos

Azka Ali, MD, discusses findings from the S0221 trial of alternative adjuvant anthracycline and taxane dosing schedules in high-risk, early breast cancer.

Azka Ali, MD

Articles

Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer